Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
FCM-R regimen
Introduction
Synonyms and keywords: FCMR regimen; FCM-R regimen; FMC-R regimen; R-FCM regimen; Rituximab-Fludarabine-Cyclophosphamide-Mitoxantrone regimen
Overview
Overview
FMC-R regimen refers to a regimen consisting of fludarabine, mitoxantrone, cyclophosphamide and rituximab, used in the treatment of resistant or relapsed chronic lymphocytic leukaemia.[1]
Regimen
Regimen
FFludarabine
MMitoxantrone
CCyclophosphamide
RRituximab
Indications
Indications
- Indolent non-Hodgkin’s lymphoma and relapsed or refractory mantle cell lymphoma.[2]
- CLL[3]
References
References
- ↑ Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B; et al. (2004). “The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group”. Blood. 104 (10): 3064–71. doi:10.1182/blood-2004-04-1323. PMID 15284112.
- ↑ “NCI Thesaurus”.
- ↑ Faderl S, Wierda W, O’Brien S, Ferrajoli A, Lerner S, Keating MJ (2010). “Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years”. Leuk Res. 34 (3): 284–8. doi:10.1016/j.leukres.2009.07.008. PMID 19646755.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]